Thomas McLain : Sure. No, we’re not commenting on the specific payment practices of the contractor that’s something that works itself out over time, but what I can say is, we’re very pleased with what that payment practice has been to date.
Mark Massaro: Okay. And then maybe just last one for me. It looks like you picked up a couple of commercial payer contracts, which is nice to see. Can you give us a sense for what your outlook looks like for commercial payer contracts for fiscal 2023? And do you think that some other payers are looking to other key achievements whether it’s a Medicare LCD or perhaps even an FDA approval? Or do you think that a lot of the conversations you’re having with payers is really around your dossier and the data that you’ve presented?
Thomas McLain: On that one, Mark, the pivotal piece of the evidence always for a payer is published peer-reviewed evidence that clinicians adopt the product that you’re offering and that it impacts care delivery. And that is the importance of the publication that was announced this week. That is real world evidence that shows a test like KidneyIntelX, which is directed to change chronic disease care in the primary care office, which has been a goal of population health initiatives across the country for a long time, but it’s showing that this test is utilized by physicians. It does change what they’re doing in the care management of patients and it benefits them clinically in as little as six months. So, for us that type of evidence for any product like KidneyIntelX that is the definitive evidence for payers that drive those coverage determinations.
So, with the publication of that data, we are strongly optimistic about our ability to expand and execute new coverage agreements in 2023.
Mark Massaro: Perfect. Congrats on the publication and I’ll hop back in the queue.
James McCullough: Thanks Mark.
Operator: Thank you.
James McCullough: So, operator, are there any other questions?
Operator: Yes. We do have one more question, and that will come from the line of Yi Chen with HCW. Please go ahead.
Yi Chen: Thank you for taking the questions. You mentioned that during the quarter, 80% of the tests were billable, do you expect the percentage to improve or remain stable going forward?
James McCullough : We would expect €“ Yi Chen, thank you. We would expect the percentage ultimately to increase with increasing coverage, but we’re actually very pleased with that percentage at the early stage . Tom, do you have anything to add to that?
Thomas McLain: No, I think that’s fair. With things like being on the clinical lab fee schedule with the coverage determinations that are in place with Medicare payment, all of those factors impact how the test is paid for, whether or not there are coverage agreements in place. And yes, overall, looking at the KidneyIntelX and the stage that we’re at with commercial launch, we’re very happy with the level of coverage that we’re seeing.
James McCullough: I think it’s important to note again that there is a large intrinsic value, which has been accumulating through the real world evidence program. The data results just published, as Tom mentioned, showing benefit within six months. We believe is exceptional and quite novel in the space. And these data results take years to put together. They’re very expensive. But once they’re in place, they now begin to continue to accumulate. So, the real world evidence program is not only very strong, but it’s growing and it will continue really on an every six month basis to put up new and additional longitudinal data to support use of KidneyIntelX primary care. And this, as Tom mentioned, goes directly to generating coverage determinations, percentage of coverage, etcetera.
So, we’re really, I believe, with insurance payment, we’re very much at an accelerating point. In 2023, we’ll continue to see regions, including large population center regions, developing comprehensive coverage across large populations.
Yi Chen: Where all the billable tests were paid at $950 per test?
